 Shares of electroCore NASDAQ:ECOR fell 3.1 in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 68.29 over the past year to 0.13, which beat the estimate of 0.21.Revenue of 753,000 higher by 20.93 from the same period last year, which missed the estimate of 860,000.Guidance electroCore hasnt issued any earnings guidance for the time being.electroCore hasnt issued any revenue guidance for the time being.Conference Call Details Date: Aug 13, 2020View more earnings on ECORTime: 04:30 PMET Webcast URL: 52-week high: 5.64Companys 52-week low was at 0.32Price action over last quarter: Up 131.21Company Description electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The companys product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients. The gammaCore is CE-marked in the European Union for the acute andor prophylactic treatment of primary headache, Bronchoconstriction and Medication Overuse Headache in adults.See more from Benzinga Earnings Scheduled For August 13, 2020 17 Healthcare Stocks Moving In Mondays Pre-Market Session 20 Healthcare Stocks Moving In Wednesdays Pre-Market SessionC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 